Summary

Location
at UCLA UCSF
Dates
study started
completion around
Principal Investigator
by Arun S. Singh, MD (ucla)
Headshot of Arun S. Singh
Arun S. Singh

Description

Summary

In this observational study researcher want to learn more about the effectiveness of drug VITRAKVI (generic name: larotrectinib) and how well the drug is tolerated during routine use in patients with TRK fusion cancer which is locally advanced or spread from the place where it started to other places in the body. TRK fusion cancer is a term used to describe a variety of common and rare cancers that are caused by a change to the NTRK (Neurotrophic Tyrosine Kinase) gene called a fusion. During this fusion, an NTRK gene joins together, or fuses, with a different gene. This joining results in the activation of certain proteins (TRK fusion proteins), which can cause cancer cells to multiply and form a tumor. VITRAKVI is an approved drug that blocks the action of the NTRK gene fusion. This study will enroll adult and paediatric patients suffering from a solid tumor with NTRK gene fusion for whom the decision to treat their disease with VITRAKVI has been made by their treating physicians. During the study, patients' medical information such as treatment information with VITRAKVI, other medication or treatments, changes in disease status and other health signs and symptoms will be collected within the normal medical care by the treating doctor. Participants will be observed over a period from 24 to 60 months.

Official Title

PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib

Keywords

Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion, larotrectinib(Vitrakvi, BAY2757556), Lung, Melanoma, Pediatric, other

Eligibility

Locations

Lead Scientist at University of California Health

  • Arun S. Singh, MD (ucla)
    HS Associate Clinical Professor, Medicine. Authored (or co-authored) 69 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Bayer
Links
Click here to find information for studies related to Bayer products. To find this study enter the ClinicalTrials.gov identifier (NCT) number or Bayer Study Identifier (ID) in the search field.
ID
NCT04142437
Study Type
Observational
Participants
Expecting 150 study participants
Last Updated